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Abstract: Targeting adenosine triphosphate (ATP) metabolism and adenosinergic signaling in cancer
is gaining momentum, as increasing evidence is showing their relevance in tumor immunology and
biology. Chronic lymphocytic leukemia (CLL) results from the expansion of a population of mature B
cells that progressively occupies the bone marrow (BM), the blood, and peripheral lymphoid organs.
Notwithstanding significant progress in the treatment of these patients, the cure remains an unmet
clinical need, suggesting that novel drugs or drug combinations are needed. A unique feature of
CLL is its reliance on micro-environmental signals for proliferation and cell survival. We and others
have shown that the lymphoid niche, an area of intense interactions between leukemic and bystander
non-tumor cells, is a typically hypoxic environment. Here adenosine is generated by leukemic cells,
as well as by cells of myeloid origin, acting through autocrine and paracrine mechanisms, ultimately
affecting tumor growth, limiting drug responses, and skewing the immune cells towards a tolerant
phenotype. Hence, understanding the mechanisms through which this complex network of enzymes,
receptors, and metabolites functions in CLL, will pave the way to the use of pharmacological agents
targeting the system, which, in combination with drugs targeting leukemic cells, may get us one step
closer to curing these patients.
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1. Introduction
Over the past years, several findings brought adenosine triphosphate (ATP) metabolism and
purinergic signaling under the spotlight of research because of their high relevance in immunology
and cancer biology. While the regulation of ATP/adenosine (ADO) homeostasis is now well defined,
with the functional characterization of the players involved, knowledge on the physio-pathological
role of the system is still incomplete. The current view in immunology is that ATP and ADO
represent a “Yin and Yang”: while ATP boosts the immune system acting as a “find-me” signal
that induces the recruitment of inflammatory cells, ADO blunts these responses. For this reason,
ATP is considered a danger signal that activates inflammatory responses and that is counteracted
by ADO, which provides a powerful stop signal, preventing excessive tissue damage [1]. Seen in
the context of cancer immunology, ADO becomes a potent immunosuppressive agent that favors
cancer expansion through the creation of an immune-tolerant and tumor-supportive environment.
Emerging data indicate that the purinergic and adenosinergic systems are not only critical in shaping
the tumor microenvironment in solid tumors, but also in hematological malignancies, including chronic
lymphocytic leukemia (CLL) [2,3].
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With an incidence rate of four to six cases per 100,000 individuals per year (Available online:
www.seer.cancer.gov), CLL is the most frequent leukemia in Europe and North America. The finding
of accumulated mature B lymphocytes in the peripheral blood (PB) led to propose CLL simply as
a disease of failed apoptosis [4]. However, CLL is now viewed as a compartmentalized leukemia with
a substantial proliferative core residing in the lymph nodes (LN) [5]. There leukemic cells find the
ideal soil, made of the antigen and a cocktail of accessory signals that drive B cell proliferation [6,7].
From the clinical point of view, it is easy to diagnose CLL, but difficult to estimate its prognosis.
Indeed, the disease is characterized by a variable clinical course, with patients presenting indolent
asymptomatic lymphocytosis alongside patients with an aggressive form of the disease associated
to immunosuppression and poor responses to therapy. This observation incited a long quest for
disease markers, which led to the identification of several prognosticators, which have increased
our understanding of the pathogenesis of the disease. Among them, chromosomal abnormalities
(e.g., deletion 17p and 11q) and mutations in different genes (e.g., TP53, NOTCH1, SF3B1) carry
prognostic significance and are associated to a shorter time to progression and a lower overall
survival [8–10]. Importantly, none of these aberrations seem to be a disease-driver, although they
commonly insist mostly on the deregulation of cell survival and recirculation [11,12].
Novel therapeutic approaches, mainly represented by kinase inhibitors, used alone or in
combination with chemo-immunotherapy are now approved for clinical use. However, results so far
indicate that while they are very effective in controlling the disease, they do not cure it, arguing in
favor of combination strategies [13]. Therefore, a dual approach concomitantly targeting leukemic cells
while relieving immunosuppression could represent a winning strategy [14]. In this context, drugs that
target the adenosinergic signaling pathway could find therapeutic applications as adjunctive tools.
This review will navigate the main aspects of the ATP-ADO axis, mainly focusing on CLL.
The key features of this system will be explored, looking at expression and functions of the main
players, along with novel pharmacological strategies that may carry therapeutic relevance.
ATP/ADO Balance: Shifting from Immune-Activating to Immune-Suppressive Signals
In healthy tissues, ATP is mainly present inside the cells, where it reaches the millimolar range,
whereas in the extracellular space it is found at low nanomolar concentration [15]. However,
extracellular ATP levels can rise sharply in conditions of cellular stress or damage [16], acting as
a beckon signal able to recruit phagocytes to inflammatory sites, promoting the clearance of
damaged cells [17]. Physiologically, it can be degraded to ADO, which counteracts ATP signals
thus representing a potent immunosuppressor [18] (Figure 1). Outside the cells, ATP is enzymatically
converted to adenosine diphosphate and adenosine monophosphate (ADP and AMP, respectively)
by ectonucleotidases belonging to three different families: alkaline phosphatases, ectonucleoside
triphosphate diphosphohydrolases (ENTPDases, including CD39/NTPDase-1), and ectonucleotide
pyrophosphatases/phosphodiesterases (ENPPs). Extracellular AMP is primarily converted to ADO
by CD73 (also known as 5′-NT), a glycosyl- phosphatidylinositol (GPI)-linked membrane-bound
glycoprotein [19–21].
ADO signaling is controlled at least in part by the enzyme adenosine deaminase (ADA), which
converts it to inosine. ADA activity is strongly dependent on its interaction with the cell surface
serine protease dipeptidyl peptidase IV/CD26, which acts as an ADA-binding protein. Alternatively,
accumulated extracellular ADO can mediate its regulatory functions by binding to one of four type 1 (P1)
ADO receptors, namely A1, A2A, A2B, and A3 [22].
All P1 receptors are G-protein-coupled, linked to calcium mobilization from intracellular
stores or cyclic-AMP (cAMP) increase. Signaling via cAMP is typically associated with significant
immunosuppression [23,24], while inhibition of cAMP generation after P1 engagement is generally
viewed as an immune-stimulating mechanism [25]. All ADO receptors couple to mitogen-activated
protein kinase (MAPK) pathways [26]. Each receptor exhibits different affinities for ADO. A1, A2A,
and A3 respond to low levels of ADO (250–700 nM), representing high-affinity receptors. On the contrary,
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A2B is a low affinity receptor which activation occurs only under pathological conditions, where ADO
accumulates at high concentration (25 µM) [27].
Figure 1. Targeting adenosine triphosphate (ATP) and adenosine (ADO): A Yin and Yang of the
immune system. ATP and ADO are present in tissues or in the tumor niche at variable concentrations.
Shifting the balance between these two metabolites results in inflammation (high ATP concentration)
or immunosuppression (high ADO concentration). Both these extremes represent a potentially harmful
condition, considering the biological consequences exerted on cells of the immune system.
ATP can be released in the extracellular space via different mechanisms, including plasma
membrane channel and lysis. Independently of the mechanism used, the final functional effects
are a consequence of the target cell and of the receptors that ATP binds to. ATP receptors, also known
as nucleotide receptors P2, comprise two subfamilies: the metabotropic P2YRs (eight members) that are
coupled via G-proteins to calcium (Ca2+) mobilization, cAMP generation and ERK/MAPK pathway
activation [28], and the ionotropic P2XRs (seven members). The latter are homo/heterotrimeric ion
channels that mediate transmembrane fluxes of Na+, K+, and Ca2+ ions [29,30]. The main signaling
mechanism used by these receptors is the alteration of intracellular ion concentration. Virtually all cell
types express one or more purinergic receptors [31], including tumor cells [32].
The existence of 15 different P2 receptor subtypes, each characterized by different selectivity/
affinity for the substrates and ability to form heteromeric structures, confers to purinergic signaling
an exclusive plasticity, allowing for rapid modulation of cellular functions in response to local changes
in nucleotide concentrations. Depending on the local nucleotide concentration changes, they can
mediate chemotaxis or retention of immune cells to inflammation/tumor sites, as well as cytokine
release, proliferation, and cytotoxicity [33].
2. The Purinergic/Adenosinergic Systems in the Tumor Microenvironment
The view of the adenosinergic network as a fine-tuned system together with its physiological
impact has gained increasing relevance also in the neoplastic context [34–36]. The solid tumor
microenvironment, as well as the lymphoid niche, are dynamic areas where cancer cells, immune
cells, fibroblasts, cytokines, growth factors and the extracellular matrix mutually interact, resulting
in tumor growth and progression, besides modification of bystander cells [37]. The environment
surrounding tumor cells is characterized by low oxygen tension [38], a condition that induces
extracellular accumulation of ATP and subsequently ADO in tumors. ATP may also accumulate
in cancer milieu as consequence of spontaneous release, tumor necrosis or chemotherapy, in turn
modulating the cross-talk among cancer and surrounding tissues.
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Whether ATP/ADO accumulation in the extracellular milieu will prove beneficial or detrimental
for the host will depend on (i) the concentration of ATP as a result of release from cells; (ii) the rate of
degradation of ATP to ADO by ectonucleotidases and (iii) the panel of receptors expressed by tumor
and infiltrating inflammatory cells. CD39 and CD73, both reported to be overexpressed in several
tumors [32], contribute to the shaping of the tumor microenvironment [39]. The catabolic activity of
CD73 is critical in generating an immunosuppressive and pro-angiogenic ADO “halo” that contributes
to cancer progression [16,40–42]. Even if purinergic receptors have emerged as central players in
tumor development, invasion and progression, acting not only on immune-infiltrating cells but also on
cancer cells, their role is somewhat controversial [43]. Activation or inhibition of selected P2 receptor
subtypes can indeed bring about tumor cell death/growth inhibition. While the relevance and impact
of ADO on the host cells as a potent immunosuppressive molecule is clear and accepted, its effects on
cancer cells remain controversial. Depending on the specific ADO receptors expressed by tumor cells,
both growth stimulation and inhibition were reported [22,32,44].
From now on, the attention of this review will be focused on CLL, dissecting expression, role and
impact of the adenosinergic/purinergic axes in leukemic and bystander cells, finally discussing their
relevance in a translational perspective.
3. Expression of the Adenosinergic Axis Machinery on CLL Cells
Similarly to solid tumor models, a role for ADO signaling in hematologic malignancies has also
been described [45]. For example, in a human model of T cell leukemia, ADO promotes leukemic cell
survival by inhibiting apoptosis induced by tumor necrosis factor-related apoptosis-inducing ligand
(TRAIL) and contributes to the multidrug resistant phenotype of leukemic cells [46]. Over the past
years, increasing evidence highlighted that deregulated surface expression of both ecto-enzymes and
ADO receptors might carry negative prognostic relevance in cancers, including melanoma, breast and
endometrial carcinomas, marking diseases with strong metastatic potential and immune tolerant
environment [47,48]. This holds true also in the context of CLL, a disease characterized by an intense
cross-talk between leukemic and non-tumor bystander cells in microenvironment-associated structures
(e.g., lymph nodes (LNs) and bone marrow (BM)), where adenosinergic signaling is integrated in the
complex network of cell-cell contacts and soluble mediators driving leukemia [49–51].
3.1. CD39 and CD73
CLL cells residing in the LN express high surface levels of both CD39 and CD73, although
some variability across samples is reported [2]. CD39 was found to be homogeneously expressed at
higher level in the Ki67+ CLL fraction compared to the resting population that showed heterogeneous
but consistently weaker expression [52]. Overall, CD39 expression was reported to be consistently
higher on circulating lymphocytes of CLL patients compared to healthy donors [53]. However,
patient stratification according to clinical and molecular prognostic markers highlighted that CD39
expression on malignant B cells is generally associated with favorable prognosis. Indeed, CD39 was
reported: (i) to inversely correlate with disease stage, being expressed at higher levels in stage 0–2 CLLs
compared to stages 3–4 and (ii) with therapy requirement, being higher in treatment-naïve patients.
In addition, expression of CD39 is enriched in samples carrying mutated IGHV genes, a common
feature in good prognosis CLL subset [53,54]. Accordingly, CD39 ATPase and ADPase activities are
enhanced in stage 0–2 CLL than in stage 3–4 [55]. The observation that expression of CD39 on CLL
cells, despite being significantly higher than healthy subjects, represents a marker of good prognosis
may sound contradictory. The explanation relies upon two considerations: (i) when looking selectively
to the B cell compartment, CD39 expression and ATPase/ADPase activity were found to be quite
similar in leukemic cells and B cells collected from healthy donors and (ii) in healthy people the T cell
fraction represents the majority of circulating lymphocytes population, at variance with CLL patients.
This prompted the idea of a major contribution of T lymphocytes in determining lower CD39 levels
in normal samples [55]. Indeed, besides leukemic cells, CLL LNs are rich of stromal components
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that are intensely CD39+, including T lymphocytes [2]. The comparative analysis of T cell subsets
highlighted that, overall, CLL patients have a higher percentage of CD39+ lymphocytes than controls,
both in the CD4+ and in the CD8+ compartment. In contrast to what has been observed in malignant B
cells, CD39 expression on T cells strongly associates with a more advanced disease stage. Consistently,
CD39+ T lymphocytes are enriched in CLL patients that need to be treated, compared to untreated
patients [56,57]. Ultimately, T-cell CD39 expression is considered predictive of treatment requirement,
as a significantly shorter time to first treatment (TTFT) was observed in patients with CD39high T cells
compared to CD39low [54].
In contrast to CD39, that is consistently present at high levels on CLL cell surface, expression
of CD73 characterizes roughly 1/3 of CLL patients [2]. In the LNs, CD73 expression is significantly
enhanced in the perivascular areas and in the proliferation centers, areas of intense leukemic cells
proliferation with infiltration of CD4+/CD25+ T lymphocytes [58]. Accordingly, CD73 expression
is higher in Ki67+ B CLL cells, which are in close contact with infiltrating T cells. When looking
at the circulating fraction, the majority of samples expresses very low levels of CD73 on cell
surface, with ≈30% CLL showing a clearly detectable CD19+/CD73+ population. CD73 expression
associates with the co-occurrence of other negative prognostic markers such as CD38 and ZAP70,
both functionally involved in the modulation of CLL homing to LN. In addition, CD73high samples
are enriched of a CD19+/Ki67+ population compared to the CD73low counterparts. Altogether, these
observations suggest that CD73 expression identifies a leukemic subset of cells characterized by:
(i) an increased recirculation to and from the lymphoid niche; (ii) a more aggressive clinical behavior;
and (iii) a higher cellular turnover [2]. Furthermore, it was proposed that higher CD73 expression
may associate with time to disease progression after fludarabine treatment [59], thus corroborating the
importance of this molecule in the CLL context.
CD39 and CD73 are also functionally active on CLL cell surface, and the metabolism of extracellular
nucleotides/nucleosides can be efficiently monitored through reverse phase high-performance liquid
chromatography (RP-HPLC), among other assays [60]. The amount of ADO resulting from sequential
CD39− and CD73− mediated reactions is compatible with the micromolar range of concentrations
reported for solid tumor tissues. It was observed that, despite virtually all CLL cells could degrade
ADP to AMP as they constitutively express CD39, a certain proportion of cells expressing CD73 is
needed to appreciate ADO production, with a cut-off of ≥30% positive cells. Furthermore, CD73+
cells consume significantly more ADP than the CD73− counterparts, probably because of the lack
of a feedback inhibitory mechanism controlled by AMP accumulation. Data obtained using specific
inhibitors suggest that CD73 is the rate-limiting enzyme in the adenosinergic axis cascade. Therefore,
ADO production in CLL is strongly dependent on CD73 expression, which is in turn tightly regulated
by signals coming from the environment [2].
3.2. CD26 and Nucleoside Transporters
Extracellular ADO can be either converted to inosine and re-uptaken by the cell through
concentrative or equilibrative nucleoside transporters (CNTs and ENTs, respectively) to reconstitute
the intracellular pool [61], or it can bind P1 receptors. Deamination to inosine is mediated by ADA,
an enzyme generally present in the cytoplasm but that can be localized on the cell surface when bound
to anchoring proteins, such as CD26 [62]. CD26 plays a significant role in CLL biology, being both
a disease marker and a modifier of tumor pathogenesis and development [63–66]. Several studies
highlighted that expression of CD26 identifies CLL patients with high-risk of disease progression and
treatment requirement [67]. Indeed, CD26 expression is strongly associated with other consolidated
negative prognostic markers as CD49d [68], CD38, ZAP-70, and unmutated IGHV [69]. In addition to
its integral membrane form, a soluble form of CD26 is detectable in the serum [70]. In the CLL field,
the prognostic value of serum CD26 is limited, as they are not consistently increased in CLL patients
compared to controls and do not correlate with other negative prognostic markers. Nevertheless,
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it was proposed that levels of soluble CD26 > 371 ng/mL might be of prognostic relevance in early
disease (stage A), as they could identify patients with shorter TTFT [71].
CLL cells express four nucleoside transporters, namely hCNT2, hCNT3, hENT1, and hENT2,
constitutively found at the mRNA level, whose protein expression is tightly modulated by different
stimuli (e.g., phorbol 12-myristate 13-acetate, lipopolysaccharide, and tumor necrosis factor α),
as well as nucleosides and nucleoside-derived drugs. The importance of nucleoside transporters
in CLL stems from the fact that anti-leukemic therapy using nucleoside-derived analogs, such as
fludarabine, depends on drug uptake and metabolic activation, and, therefore, the modulation of
transporter expression on the cell surface may affect drug bio-availability [72]. Despite the apparent
co-expression of these four transporter genes in CLL cells, most of the measurable natural nucleoside
transport and all detectable fludarabine uptake into CLL cells rely on hENT-type carriers [73]. It was
also documented that hENT2 protein expression significantly correlates with response of CLL cells to
fludarabine ex vivo, potentially predicting therapeutic outcome in the clinical practice [74].
3.3. P2 and P1 Receptors
Among purinergic receptors, P2X7 is the most studied in cancer models [75,76] and several studies
showed that it is the main ATP-activated channel in lymphoblastoid cells [77,78]. More recently, P2X7
over-expression has been suggested as a negative prognosticator in several malignancies, including
prostate cancer [79], acute myeloid leukemia [80] and CLL [81,82].
Functional data on P2X7 in CLL are contradictory, with one paper suggesting that it may improve
growth of CLL cells [82], while a second one highlighted its pro-apoptotic functions [83]. Adinolfi and
colleagues reported that P2X7 expression and function are increased in CLL lymphocytes purified
from patients with progressive disease, compared to patients with an indolent form of leukemia.
The authors speculated that a higher expression of this receptor would result in a growth advantage
for the leukemic clone, especially in unfavorable conditions, including limited availability of substrates
or serum-derived growth factors [84]. They also showed that CLL cells exposed to high levels of
exogenous extracellular ATP are more susceptible to its cytotoxic effect, through P2X7 activation and
consequent stimulation of intracellular caspases, leading to apoptosis. Even if these results seem to
be paradoxical, they are in line with what reported for other cellular models and can be explained
by the diverse array of intracellular signals generated. In fact, under tonic low-level activation, P2X7
promotes survival and growth, but under massive stimulation, it triggers cell death [84,85].
P2X7 is the most polymorphic P2 receptor. Wiley and co-workers reported a single-nucleotide
polymorphism (SNP) consisting of an adenine to cytosine substitution at position 1513 (1513A→C),
resulting in the conversion of a glutamic acid to alanine at position 496 (E496A). This non-synonymous
SNP is responsible for a loss of function of the P2X7, while not affecting its expression [86].
The SNP is also present at a greater frequency (three-fold increase) in a cohort of CLL patients
characterized by an indolent disease compared to normal individuals [83]. Patients homozygous
for the polymorphic allele show no P2X7 function, while heterozygous ones are characterized by
an intermediate activity compared to wild-type homozygous individuals. The rate of ATP-induced
apoptosis varies accordingly.
However, these results were not confirmed by subsequent studies. Rosenquist and colleagues
reported that in a retrospective analysis in a cohort of 170 CLL patients and 200 healthy controls
similar frequencies of the 1513C allele were found. Within the CLL cohort, the frequency of 1513C is
independent of different prognosticators of the disease, including the immunoglobulin heavy chain
(IGHV) mutational status [87]. Analysis on other large independent cohorts reached similar results
with no correlation with age or stage at diagnosis, time to first treatment, progression-free survival
and other prognostic markers [88–90]. Taken together, these results suggest that is unlikely that 1513C
P2X7 polymorphism may have a significant role in the pathogenesis or progression of CLL.
Considering ADO receptors, only A2A is highly expressed by CLL cells, whereas levels of A1, A2B,
and A3 are barely detectable and their role in CLL has not been yet addressed [2]. A2A is the receptor
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most commonly involved in anti-inflammatory and antitumor responses [91]. Compared to age- and
sex-matched healthy donors, CLL patients show significantly higher levels of A2A and the expression
of this receptor is further increased in response to signals inducing CLL proliferation, such as TLR9
agonists and IL-2. In addition, A2A levels in CLL cells do not show any evident correlation with
CD73 surface expression, further corroborating the idea that CD73 represents the limiting factor in the
adenosinergic axis activation in CLL [2].
4. ADO Signaling in CLL Cells
The A2A receptor on CLL cells is functionally active as, in response to a specific agonist (CGS21680),
intracellular cAMP concentrations increase because of the activation of the receptor-coupled
stimulatory G proteins. Exposure of CLL cells to TLR9 agonists and IL-2 further enhances cAMP release
in response to CGS21680, confirming that in activated CLLs the adenosinergic axis is boosted [2].
Signaling downstream of ADO receptors is a fundamental component of the immunosuppressing
machinery having regulatory T cells as main players and blunting T cell proliferation and secretion of
T-helper 1 (Th1) cytokines [92]. However, less characterized are the effects that the adenosinergic axis
exerts through autocrine mechanisms on leukemic cells, effects that impact on critical features of CLL
biology, such as homing and survival.
4.1. ADO Signaling Modulates CLL Cells Homing
The finding that CD73 expression in CLL LNs is higher on cells residing in perivascular areas,
along with its association with CD38 and ZAP70, both markers of cells with high recirculating
ability, suggested that the adenosinergic axis might be relevant in the homing process and in tuning
chemotactic responses in CLL. Several pieces of evidence in literature highlighted that adenosinergic
signaling modulates the migration of both tumor and immune cells [93,94]. In other tumor models,
A2A effects are believed to be due to the down-modulation of chemokine receptors on cell surface [95],
or on receptor desensitization by cAMP [96]. In line with these observations, CD73-produced ADO
inhibits CLL cell migration toward C-X-C motif chemokine 12 (CXCL12), one of the major drivers of
lymphocytes recirculation to and from LNs [97]. The proposed mechanism behind this effect relies
upon ADO-mediated down-modulation of chemokine receptors, as intensity of C-X-C chemokine
receptor type 4 (CXCR4) levels expressed on CLL is significantly decreased in the CD73+ subset
compared to CD73− [2]. The inference would be that leukemic B cells are attracted to LNs because
of the long-range signal provided by CXCL12 and other chemokine gradients, whereas local ADO
triggers a short-range stop signal capable of keeping cells in a growth-supportive environment.
4.2. ADO Signaling Rescues CLL Cells from Spontaneous- or Drug-Induced Apoptosis
One of the major contributions of LN microenvironment to CLL is to provide survival signals to
leukemic cells and to protect them from spontaneous and drug-induced apoptosis, thereby maintaining
a leukemic cell reservoir that fuels disease progression [13]. The role of ADO on apoptosis is controversial,
as both pro-apoptotic [98] and cyto-protective [99] effects have been reported. One possible explanation
relies on the expression of different ADO receptors capable of inducing or blocking the synthesis of
intracellular cAMP thereby modulating its concentrations. In the CLL field, Serra and co-authors
demonstrated that extracellular ADO protects cells both from spontaneous and drug-induced apoptosis,
in a range of concentrations compatible with that of CD73-mediated ADO generation by CLL cells.
ADO exerts a dose-dependent protective effect counteracting or limiting the efficacy of different
chemotherapeutic agents independently of their mechanism of action. For example, in vitro, ADO
significantly impairs the effects of etoposide, a DNA-damaging drug that rapidly triggers robust
apoptosis in CLL. This effect can be recapitulated by the selective A2A agonist CGS21680, and is
completely lost if cells are pretreated with the A2A inhibitor SCH58261, indicating that ADO-mediated
protection from apoptosis is mainly acting through the A2A receptor. In line with this observation,
inhibition of CD73 resulted in a small decrease in cell viability when used as a single agent, but acted
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synergistically with etoposide strongly potentiating the apoptotic effect of chemotherapy. Addition
of exogenous ADO rescues cells from apoptosis confirming the key role of CD73 in fueling CLL cells
with ADO. From a functional standpoint, exposure of leukemic cells to ADO in combination with
etoposide results in the modulation of the expression of p53-dependent elements, including Mcl-1 and
BAX, finally resulting in a decreased activation of caspase-3 [2]. These observations are consistent with
results highlighting a protective effects induced by intracellular cAMP through the activation of the
NF-κB pathway, which in turn impairs the apoptotic machinery triggered by p53 [100,101].
Similar effects were observed when exposing CLL cells to fludarabine, where ADO conferred
complete protection to CLL cells, although the effect is not fully recapitulated by the A2A agonist,
opening to the possibility that in this context ADO should act through both A2A-dependent and
-independent mechanisms [2]. The explanation may rely upon the remarkable similarity in the structure
of ADO and fludarabine, likely competing for nucleoside transporters [59] and for intracellular effectors.
According to this hypothesis, in the presence of high amount of extracellular ADO, fludarabine
would have a limited access to its final targets, in line with one of the suggested mechanisms behind
fludarabine resistance in leukemia [72].
5. ADO in the CLL Niche Is Part of a Network of Micro-Environmental Signals
Recent data shows that the CLL niche within the LN is a highly hypoxic microenvironment
where low oxygen tension activates a specific genetic program mainly through the regulation of
HIF1α [102]. HIF1α modulates the expression of several molecules involved in the leukemic niche
dynamics, including chemokine receptors and cell adhesion molecules, such as CXCR4 and VLA-4
respectively, suggesting that it plays a role in controlling the cross-talk of leukemic cells with BM and
spleen microenvironments. Remarkably, HIF1α mRNA levels in circulating CLL vary significantly
within patients, and HIF1α is upregulated, at the transcriptional level, in leukemic cells upon contact
with stromal cells in a positive feedback loop that may foster CLL expansion and protection [103].
For this reason, it was recently proposed that HIF1α mRNA overexpression in circulating B cells
might be considered a promising independent molecular marker for adverse prognosis CLL [104].
When comparing HIF1α expression in leukemic cells collected from paired peripheral blood (PB), BM,
and LNs of CLL patients, mRNA levels are the highest in LN, together with known HIF1α target
genes. Accordingly, immunohistochemical analyses of HIF1α and its target carbonic anhydrase IX
(CAIX) indicate the presence of a hypoxic gradient in CLL LN with an inverse correlation between the
intensity of CAIX staining and the distance from vessel, and highlight the proliferation centers as the
areas with the lowest oxygen tension [3].
Several pieces of evidence highlighted that hypoxia acts through ADO signaling in inflammation
and cancer [105–108] and specifically activating, at least in part, the A2A receptor signaling. It was
proposed that tumor protection from CD4+ and CD8+ T cells is due to a large extent to the inhibition of
antitumor T cells by hypoxia-driven local accumulation of extracellular ADO in the microenvironment,
resulting from tumor metabolic adaptation to low oxygen tension [109]. A reciprocal cross-talk between
hypoxia and adenosinergic axis has been reported with HIF1α directly regulating the expression of
elements of ADO signaling [110]. This holds true also for CLL where the overexpression and activation
of HIF1α in the LN increases ADO generation and signaling, affecting tumor and host cellular responses
(Figure 2).
5.1. Hypoxia Boosts the Adenosinergic Axis in CLL Cells
Experimental evidence shows that CD73 expression is significantly upregulated under in vitro
hypoxic conditions, both at the mRNA level (NT5E) and on CLL cell surface [3], in line with previous
observation of a direct transcriptional control of NT5E by HIF1α [111]. This effect is restricted to the
CLL subset with >30% CD19+/CD73+ cells as no significant modulation is observed in the negative
subset. These data, along with the fact that CD39 expression levels remain unmodified upon oxygen
tension variation, further consolidate the pivotal role of CD73 in the adenosinergic axis. All the
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sequential steps of the AMP degradation chain downstream of CD73 are markedly upregulated in
response to hypoxia, as indicated by significant increases in the expression of CD26 together with
nucleoside transporters (ENT1 and ENT2) and A2A receptor. This expression profile suggests that
under hypoxic conditions, CLL cells upregulated the enzymatic machinery for ATP scavenging with
rapid degradation of ATP to inosine and subsequent cellular uptake. Consistently, CLL samples
collected from LN show a strong upregulation of CD73, CD26, ENT1-2, and A2A, which are expressed
at significantly higher levels compared to paired PB samples, fostering the idea of a strong ADO
signaling in the LN compartment [3].
Figure 2. ADO in the chronic lymphocytic leukemia (CLL) lymphoid niche is part of a complex network
of micro-environmental signals. The CLL niche is a hypoxic environment, as witnessed by high levels
of HIF1α compared to reactive lymph nodes (LN) from healthy individuals. HIF1α modulates the
adenosinergic axis both in bystander and CLL cells. These populations expressed on their cell surface
the enzymatic machinery to dismantle ATP/ADP/AMP, generating ADO. This nucleoside can exert
paracrine or autocrine effects, mediated at least in part through the binding to A2A receptor, or can be
dismantled to inosine.
5.2. Hypoxia Fosters the Adenosinergic Axis in “Not So Innocent” Bystander Cells of the Leukemic Niche
When CLL cells are cultured under hypoxic conditions, they do not accumulate ADO in the
extracellular space, likely because this nucleoside is rapidly converted to inosine, as the adenosine
deaminase activity is also upregulated under hypoxia. This observation suggests that the hypoxia-ADO
circuit is not merely restricted to leukemic cells through an autocrine self-fostering mechanism,
but involves other elements of the LN environment in a more complex network of interactions. Indeed,
hypoxia induces a strong upregulation of the adenosinergic axis also in nurse-like cells (NLCs), a type
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2 (M2) macrophage population residing in the LN that secretes cytokines supporting tumor growth
and suppressing immune response [112]. When derived in vitro and exposed to low oxygen tension,
NLCs significantly upregulated CD73 levels and ADO production, thereby fueling A2A signaling
of surrounding cells as well as activating autocrine signaling through MAPK, PI3K, and NF-κB [3].
Indeed, expression of A2A is also increased in NLCs upon hypoxia and signaling through ADO
receptor further contributes to M2 macrophage polarization, as revealed by gene expression
profiling. Hypoxia upregulates, among others, the expression of the transcription factor IRF4 and
of the tryptophan-metabolizing enzyme indoleamine 2,3-dioxygenase (IDO), both M2 macrophages
markers [113], and this effect is prevented by A2A antagonist. Furthermore, the hypoxia-ADO
signaling strengthens the growth-supportive ability of NLCs by increasing synthesis of IL-6, which
confers growth advantage to CLL cells. Therefore, the major inference of ADO signaling activation in
the CLL microenvironment is the re-shaping of a tumor-favorable niche with tumor-supportive
and immunosuppressive features. This holds true also when looking at the T cell population.
ADO mediates the hypoxia-induced impairment of T cell proliferation in response to activatory
stimuli, such as anti-CD3/CD28 ligation, and promotes the development and expansion of a T cell
population with regulatory phenotype and suppressive properties (Tregs).
5.3. Hypoxia Contributes to Metabolic Skewing of Cells in the Leukemic Niche
CLL T lymphocytes cultured under hypoxic conditions switch their metabolism toward glycolysis,
with robust upregulation of glucose and lactate transporters and of lactate dehydrogenase (LDHA)
and pyruvate kinase 2 (PKM2) [3]. In line with the observation that metabolic switch toward glycolysis
skews T cells functions to a regulatory phenotype [114], CLL T lymphocytes increase the expression of
FOXP3 together with PD-1, IL-10, and VEGFA. In contrast, mRNA levels of interferon γ (IFNG) are
markedly reduced, and these effects can be recapitulated upon pharmacological modulation of A2A
activation [3].
Metabolic adaptation upon oxygen deprivation is a common feature of tumor cells that
rapidly foster energy production via glycolysis through HIF1α-mediated transcriptional control [115].
Accordingly, at 1% O2 leukemic B cells markedly increase glycolysis as evaluated both through the
dynamic monitoring of metabolic responses and the expression of glycolysis genes such as those
encoding the glucose transporter GLUT1 (SLC2A1), LDHA, the lactate transporter monocarboxylate
transporter 4 MCT4 (SLC16A3), and PKM2. Once again, this effect is partly mediated through the
activation of ADO signaling, as indicated by the complete reversion of the glycolytic behavior of CLL
cells upon the addition of A2A inhibitor, directly linking ADO signaling to central metabolic programs.
This prompts the idea that leukemic cells in the areas of intense proliferation undergo a hypoxia-driven
ADO-mediated metabolic adaptation with a shift towards glycolysis for the correct energy supply [116].
In keeping with the immunomodulatory effects registered in the T cell compartment, the pattern of
metabolic changes induced by the hypoxia-ADO axis on leukemic B cells also plays an important
role in creating local conditions of immunosuppression by tuning cytokine production and release.
CLL cells cultured under hypoxic conditions acquire a B-regulatory phenotype as defined by a marked
upregulation of IL-10 [117], that is prevented upon A2A antagonist, thus confirming that in CLL
microenvironment hypoxia and ADO function in a common signaling axis [3] (Figure 3).
5.4. Targeting the Adenosinergic Pathway
As highlighted in this review, in CLL, as well as in several cancer models, the activity of ATP and
its derived metabolites is critical for cancer growth and polarization of the immune system toward
a tumor-supportive condition. Thus, it is reasonable to hypothesize to target purinergic/adenosinergic
signaling in the fight against cancer. This could result in direct effects on cancer cells through the
reduction of the ADO levels present in the tumor microenvironment as well as in the re-activation of
the host response by the maintenance of increased levels of ATP able to activate purinergic receptors
and to recruit immune cells into the tumor.
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This paragraph will explore how these pathways have been targeted in several tumor models
showing that ADO scavenging prevents tumor progression and metastasis. These different approaches
are presented here because they could be applied to CLL, where at the moment only very few
preliminary data are available. Distinct levels of targeting can be suggested in the attempt to lower
extracellular concentrations of this nucleoside and modulate its effects. First, a decrease of ADO can
be obtained through the downregulation of CD39 and/or CD73 [118–120] or through the upregulation
of CD26 or ADA. Several CD39 inhibitors, including ARL67156 and POM-1, have shown efficacy in
animal models of follicular lymphoma, sarcoma, or murine melanoma, resulting in a partial overcome
of T-cell hypo-responsiveness to stimulation [121], increased therapeutic response to chemotherapeutic
agents [122], or inhibition of tumor growth [123], respectively. Even the use of specific anti-CD39
antibodies able to interfere with the enzymatic activity of the molecule seems to be effective in the
tumor context, as recently reported in sarcoma and ovarian cancers [124–126]. The promising value
of targeting the CD39-CD73-ADO cascade as an anti-tumor therapy has been further demonstrated
by treatment of mice with an anti-CD73 antibody that curbs the development of lung metastases
in a breast tumor model [120]. Similar results were obtained by other groups [118,119,127–130].
Highly promising in a translational perspective is the compound a,b-methylene-ADP (APCP), the most
potent competitive CD73 inhibitor [45,131,132]. A therapeutic anti-CD73 antibody, MEDI9447 is
currently in Phase 1 clinical trial in cancer patients (NCT02503774) [133,134].
Figure 3. Adenosine-mediated immunosuppression in the CLL lymphoid niche. CLL cells can
recirculate from the periphery to lymphoid organs following chemokine gradients, including CXCL12.
Once in the tumor niche, leukemic cells are in closed contact with macrophages (MΦ)/nurse-like
cells, mesenchymal cells (MSC), follicular dendritic cells (FDC) and T lymphocytes. These areas are
characterized by low oxygen tension and high concentrations of ADO, which forms a halo able to
protect CLL cells from the effects of chemotherapy, while increasing proliferation, survival and shifting
their metabolism towards a glycolytic one. At the same time, ADO skews T cells and macrophages
towards an immune-tolerant and CLL-supportive phenotype, mediated also through the secretion of
specific cytokines (IL-6/IL-10).
A second level of targeting is represented by the blockade of the A2A/A2B ADO receptors
or the activation of the A3. Several studies have shown that administration of A2A antagonists
can enhance anti-tumor immunity in preclinical models [135–137]. Moreover, targeting both tumor
and host A2B has been reported to decrease tumor growth and metastasis, promoting anti-tumor
immunity [47,138–140]. At least three different A2A antagonists are in Phase I clinical trials (CPI-444,
PBF-509, and AZD4635), both alone and in combination with anti-PD1/PD-L1 therapy for solid tumors.
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Recently, a dual A2A/A2B inhibitor, AB928, has been designed to overcome potential compensatory
mechanisms due to the inhibition of one of these two receptors [141]. AB928 is in phase I trial in
healthy volunteers and expect to initiate a phase 1/2 trial in cancer patients in the first half of 2018.
A third level of control and targeting of the adenosinergic signaling is the downregulation of
ADO receptor. In adoptive immunotherapy, anti-tumor effector cells may be manipulated to be
irresponsive to ADO by silencing receptor expression with siRNA or by exposing the cells to ADO
receptor agonist. These treatments result in the abrogation of ADO-mediated immunosuppression in
tumor microenvironment, promoting, at the same time, eradication of tumor cells by immune system.
Otha and colleagues showed that silencing of A2A in T cells inhibited tumor growth and metastasizing
while preventing neo-vascularization [23,142].
Given the promising results obtained by a single-agent targeting, combination strategies can
synergistically enhance anti-tumor immune responses. As immune cells infiltrating the tumor
co-express CD39 in association with other co-inhibitory molecules (e.g., CTLA4 and PD-L1),
a combinational approach targeting both CD39, CD73, and co-inhibitory molecules has been proposed.
The aim is to control the immunosuppressive potential of ADO signaling while minimizing the side
effects of anti-CTLA4 and anti-PD1 blockade [124,130,143–145]. Inhibition of ADO signaling has been
shown to synergize with anti-PD-1 or anti-CTLA-4 mAbs in preclinical studies [129,135,137]. Phase 1
clinical trials evaluating CD73 or A2A blockade in combination with PD-1/PD-L1 inhibitors are
currently being conducted (NCT02503774 and NCT02655822). Targeting A2A or CD73 in combination
with adoptive cell therapy is another promising combination [45]. Accumulating evidence suggests
that chemotherapy [146] and radiotherapy [147] can also synergize with immunotherapies. Consistent
with this notion, inhibition of CD73, A2A, or A2B has been shown to enhance the activity of
chemotherapy [47,127,139].
What is the state-of-the-art of targeting the adenosinergic axis in CLL? There are only few papers
addressing this point. In a study published in 2005, Balakrishnan and co-workers demonstrated
that leukemic lymphocytes treated with 8-Cloro-Adenosine (8-Cl-Ado) were characterized by a time-
and dose-dependent increase of 8-Cl-ATP, with a concomitant decrease of the endogenous ATP pool.
Inhibition of global RNA synthesis resulted in a significant decline in the expression of transcripts
involved in the apoptotic pathway, including Myeloid cell leukemia-1 (MCL1), a key survival factor
for CLL cells. Furthermore, 8-Cl-ATP resulted in programmed cell death, as inferred by multiple
read-outs including caspases activation, cleavage of caspase-3, and PARP (poly-adenosine diphosphate
[ADP]-ribose polymerase), and enhanced DNA fragmentation. These results indicated that 8-Cl-Ado
is able to induce apoptosis in CLL lymphocytes by targeting cellular bioenergy as well as RNA
transcription and translation of key survival genes such as MCL1 [148]. This nucleoside analogue has
entered a phase I-II clinical trial for patients with CLL (NCT00714103) and acute myeloid leukemia
(AML) (NCT02509546) and Stellrecht and colleagues showed that it acts by inducing autophagy in
CLL cells both in vitro and in vivo during therapy [149].
5.5. Future Perspectives
The increasing literature highlighting the clinical benefits of targeting the adenosinergic pathway
in cancer, together with in vitro data underlying its functional role in CLL, open the way to novel
additional therapeutic strategies needed as none of the current treatment options for CLL are ultimately
disease curative.
To this purpose, the Eµ-TCL1 mouse model [150], based on the adoptive transfer of spleen-purified
leukemic cells in naïve C57BL/6 immunocompetent recipients, represents a useful tool to study CLL
and for preclinical analyses. Concerning the adenosinergic axis, data so far obtained indicate that CD39
is expressed at very high levels by TCL1 leukemic cells compared to the normal B cell counterpart from
naïve mice. Similar to CLL patients, high heterogeneity in CD73 expression is observed, supporting
the idea of variable levels of ADO in tissue colonized by leukemic cells. Moreover, leukemic cells are
characterized by low levels of CD26 in contrast to wild-type B cells [151].
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Specific T cell and myeloid subset changes are associated with CLL development. Indeed, TCL1
mice are characterized by a drop of the naïve T cell subset compared to WT mice, with simultaneous
over-representation of memory, exhausted and regulatory T cell sub-populations, in line with published
data [152,153]. Similarly, the monocyte compartment undergoes major shifting towards an M2
tumor-supportive phenotype, with the patrolling population overcoming the inflammatory one,
consistent with data reported by Hanna and colleagues [154]. Taken together, these results show
that the adenosinergic axis is over-expressed in the TCL1 mouse model and that the presence of
leukemic cells polarizes the host immune system, favoring the establishment of a tumor supportive
environment [151]. These observations confirm what described for CLL patients and pave the way to
test the impact of ADO-targeting therapies, alone or in combination with drugs that directly target the
leukemic clone to magnify therapeutic responses.
6. Concluding Remarks
The emerging picture in cancer therapy is that better results in terms of clinical responses can
be achieved by a “double hit” strategy, targeting tumor cells and tumor-host interactions. For these
reasons, a deep characterization of all the mechanisms contributing to cancer development, progression,
and immune-escape is an essential step. Nucleotides, nucleosides, and their receptors are part of this
network and they play a critical role in contributing to cancer cells growth and in shaping the tumor
microenvironment through different circuits.
In vitro and in vivo results from several tumor models strongly indicate that altering the balance
between ATP and ADO, thus interfering with the adenosinergic axis, has significant antitumor effects.
This approach could represent a winning strategy also for CLL. CLL is a hematological malignancy
strongly dependent on tumor microenvironment interactions to derive growth signals as well as
protection from drugs and immune system. In this context, the leukemic niche is a safe environment,
contributing to the maintenance of disease reservoir. CLL niche is a hypoxic environment that fosters
the adenosinergic axis by generating a tumor-protective halo of ADO, through the modulation of the
enzymatic machinery able to dismantle ATP and the receptors capable of using ADO. The final results
are cytoprotection of leukemic cells from chemotherapy and modulation of immune system responses
through the polarization of T and myeloid cells towards a pro-tumorigenic phenotype. Thus, it is
reasonable to hypothesize that in CLL the adenosinergic axis may be a good candidate for targeting
acting at two different levels: on one side, by preventing the generation of an ADO-protecting halo
and on the other side by awaking the immune system against the leukemic cells.
The whole picture that emerges from this increasing body of results paves the way to further
investigate on the adenosinergic/purinergic signaling in CLL and on the potential impact of interfering
compounds, opening promising perspective to develop novel therapeutic strategies.
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